Table 6 |
||||
|
Traditional treatment usage by seizure group. |
||||
|
Treatment |
Overall |
Controls |
Clinical Seizures |
Subclinical Seizures |
|
|
||||
|
Anti-epileptic drug treatment |
||||
|
Valproic acid |
31% |
6% |
39%† |
48% †,ns |
|
|
||||
|
Lamotrigine |
22% |
3% |
27% † |
39%†, ns |
|
|
||||
|
Levetiracetam |
18% |
1% |
23% † |
31% †,ns |
|
|
||||
|
Carbamazepine |
18% |
1% |
26% † |
23% †,ns |
|
|
||||
|
Topiramate |
17% |
1% |
25% † |
22% †,ns |
|
|
||||
|
Oxcarbazepine |
16% |
2% |
22% † |
24% †,ns |
|
|
||||
|
Clonazepam |
12% |
3% |
16% † |
13% †,ns |
|
|
||||
|
Phenytoin |
10% |
1% |
13% † |
13% †,ns |
|
|
||||
|
Phenobarbital |
10% |
2% |
14% † |
11% †,ns |
|
|
||||
|
Gabapentin |
7% |
1% |
8% † |
12% †,ns |
|
|
||||
|
Zonisamide |
7% |
0% |
10% † |
12% †,ns |
|
|
||||
|
Ethosuximide |
4% |
0% |
4% ns |
10% †, ns |
|
|
||||
|
Felbamate |
4% |
0% |
5% † |
7% †,ns |
|
|
||||
|
Non-antiepileptic drug treatments |
||||
|
|
||||
|
Vitamin B6 |
19% |
27% |
15% † |
20% ns,ns |
|
|
||||
|
Steroids |
11% |
21% |
5% † |
14% ns, ns |
|
|
||||
|
Ketogenic diet |
6% |
0% |
7% † |
13% †,ns |
|
|
||||
|
Intravenous Immunoglobulin |
3% |
1% |
3% ns |
7% ns,ns |
|
|
||||
|
Vagal Nerve Stimulator |
3% |
0% |
4% ns |
6% ns,ns |
|
|
||||
|
†p < = 0.0001 For each treatment listed, statistical comparisons were made between the clinical seizure group and the control group (superscript after the clinical seizure percentage), the subclinical seizure group and the control group (1st superscript after the subclinical seizure percentage) and between the clinical and subclinical seizure group (2nd superscript after the subclinical seizure percentage). There are 18 treatments and 3 comparisons for each treatments resulting in 54 comparisons. The Bonferroni correction results in an alpha of 0.05/54 = 0.0009, so we have set the alpha to p < = 0.0001 to be conservative. |
||||
|
Frye et al. BMC Pediatrics 2011 11:37 doi:10.1186/1471-2431-11-37 |
||||
